Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

45.31 +0.22 (+0.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 362,548
Open 44.88
Bid (Size) 43.73 (1)
Ask (Size) 48.43 (1)
Prev. Close 45.09
Today's Range 44.08 - 45.58
52wk Range 37.82 - 79.40
Shares Outstanding 59,983,533
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Where Blueprint Medicines Stands With Analysts
 
Via Benzinga

Performance

YTD
+4.64%
+4.64%
1 Month
+4.14%
+4.14%
3 Month
+5.45%
+5.45%
6 Month
-35.37%
-35.37%
1 Year
-28.72%
-28.72%

More News

Read More
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Via Benzinga
Earnings Scheduled For February 16, 2023
Via Benzinga
Earnings Preview For Blueprint Medicines
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
9 Analysts Have This to Say About Blueprint Medicines
Via Benzinga
Recap: Blueprint Medicines Q3 Earnings
Via Benzinga
FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
Via Benzinga
Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Uber To Rally Around 82%? Here Are 5 Other Price Target Changes For Wednesday
Via Benzinga
NASDAQ:BPMC Investor Notice: Investigation over Potential Wrongdoing at Blueprint Medicines Corporation
Via SBWire
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Via Benzinga
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC
Via NewMediaWire
Blueprint Medicines Corporation (NASDAQ:BPMC) Investor Notice: Investigation over Possible Violations of Securities Laws
Via SBWire
What 14 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.